QPS buys major stake in JSW Life Sciences

JSW provides preclinical and clinical Phase II – IV drug development services including project planning, project management, trial monitoring, database management, data analysis, medical writing and regulatory affairs.

In addition, JSW provides genetically modified organisms for research in CNS diseases and combines behavioral analysis (cognition and motoric function), brain neurochemistry and biochemistry as well as quantitative histology and histopathology into preclinical research.

JSW also has the capability to access to biomarker technologies including A4-assay for A-beta oligomers from Amorfix.

QPS said the acquisition of JSW’s clinical division will extend its Netherlands’ later-stage site-monitoring capability to most of Central and Eastern Europe, as well as provide additional project management capabilities.

JSW Life Sciences CEO Manfred Windisch said, "Integrating JSW with QPS will afford us more global exposure and market competitiveness, and also allow us to offer complete services from preclinical to clinical."

QPS CEO Ben Chien said with the acquisition, clients will now have access to an even wider range of services they have come to expect from QPS, along with an expanding global footprint.

"This strategic expansion in our preclinical service offerings and Phase II-IV clinical capability represents our fifth cross-border acquisition, thereby pushing QPS further up as a high-quality contract research provider in the ranks of the global CRO business space," Chien added.